Page 6 - Mark Mintun News Today

Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large...

New research shows another experimental Alzheimers drug can modestly slow patients inevitable worsening

Second Alzheimer's Drug Promises To Slow Worsening

Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.

Alzheimer’s disease patients in the earliest stages of their disease benefited the most from Eli Lilly drug donanemab, which is expected to receive an FDA decision by the end of 2023. Full results from the drug’s pivotal study were presented during the during the Alzheimer’s Association International Conference.

Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.

Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.

Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.

Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.

Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.